IBJNews

Pressure rises as Lilly tries squeeze play

Back to TopCommentsE-mailPrintBookmark and Share

Call it Lilly’s squeeze play.

Indianapolis-based Eli Lilly and Co. is now in the predicament of watching revenue fall as its patents on older products expire, even as the company needs to spend more money on marketing and research to boost sales of new drugs.

Lilly hopes it can score a run by launching new products before its high level of spending gets it thrown out at first base.

But its margin for error is even smaller than Wall Street analysts expected, which bumped Lilly’s stock price down a notch late last week. Lilly expects its 2012 profits to range between $3.10 and $3.20 per share, compared with analysts’ estimates of $3.61 per share.

Sales of Zyprexa, Lilly’s best-selling drug that lost patent protection in October, are falling faster than expected in international markets. Analysts thought the drug would bring in $2.1 billion this year, but Lilly now expects $500 million less than that.

Analysts also thought Lilly would reduce its spending this year compared with 2011—chopping $300 million—but now the firm says that’s not to be. It needs to boost sales efforts on its existing products. And it has to keep pouring money into its drug pipeline, which currently has an unprecedented 66 molecules in human trials. Twelve of those are in Phase 3, the final testing stage before regulatory approval.

“We’ve successfully rebuilt our mid- to late-stage pipelines to position Lilly for growth post-2014,” Derica Rice, Lilly’s chief financial officer, said during a Jan. 5 conference call with analysts and investors. But, he added, “the growth in our Phase 3 pipeline will ... create upward pressure on R&D spend.”

Lilly’s bet is that it can get enough of those molecules approved as new products to offset its loss of Zyprexa sales, as well as sales of four other blockbusters that are seeing patents expire by 2013.

But doing that requires money, something Lilly will have less of over the next three years. That’s not to say the company can’t afford that; it’s just a question of how much it has to chop its profits—or its work force—to get it done.

Lilly executives have been adamant that the company’s revenue won’t fall below $20 billion (from more than $24 billion last year) and its profits won’t dip below $3 billion (compared with nearly $5 billion last year).

To help in that process, Lilly over the past two years eliminated 5,500 jobs and cut its expenses $1 billion. But Citbank analyst John Boris doesn’t see how Lilly can stay above its minimum revenue and profit goals without more cuts—$900 million of them, he estimates.

“Therefore, we expect LLY to implement some level of cost cutting by [year’s end],” wrote Boris, referring to Lilly by its ticker symbol, in a Jan. 6 note to investors. And because he doesn’t expect Lilly’s pipeline to produce enough new sales to replace expiring blockbusters, Boris said Lilly will have to acquire more companies to get its sales and profits growing after 2014.

But not every analyst agrees entirely. Barclays Capital analyst Tony Butler expects Lilly’s pipeline to produce annual sales ranging between $2.5 billion and $4.5 billion by as early as 2015. And by 2020, he said, Lilly’s new products could be racking up $14 billion each year.

“However,” Butler noted, “these pipeline assets [which include the heart drug evacetrapib and the rheumatoid arthritis drug LY3009104], would require a significant amount of continued R&D investment.”

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Really, taking someone managing the regulation of Alcohol and making himthe President of an IVY Tech regional campus. Does he have an education background?

  2. Jan, great rant. Now how about you review the report and offer rebuttal of the memo. This might be more conducive to civil discourse than a wild rant with no supporting facts. Perhaps some links to support your assertions would be helpful

  3. I've lived in Indianapolis my whole and been to the track 3 times. Once for a Brickyard, once last year on a practice day for Indy 500, and once when I was a high school student to pick up trash for community service. In the past 11 years, I would say while the IMS is a great venue, there are some upgrades that would show that it's changing with the times, just like the city is. First, take out the bleachers and put in individual seats. Kentucky Motor Speedway has individual seats and they look cool. Fix up the restrooms. Add wi-fi. Like others have suggested, look at bringing in concerts leading up to events. Don't just stick with the country music genre. Pop music would work well too I believe. This will attract more young celebrities to the Indy 500 like the kind that go to the Kentucky Derby. Work with Indy Go to increase the frequency of the bus route to the track during high end events. That way people have other options than worrying about where to park and paying for parking. Then after all of this, look at getting night lights. I think the aforementioned strategies are more necessary than night racing at this point in time.

  4. Talking about congestion ANYWHERE in Indianapolis is absolutely laughable. Sure you may have to wait in 5 minutes of traffic to travel down BR avenue during *peak* times. But that is absolutely nothing compared to actual big cities. Indy is way too suburban to have actual congestion problems. So please, never bring up "congestion" as an excuse to avoid development in Indianapolis. If anything, we could use a little more.

  5. Oh wait. Never mind.

ADVERTISEMENT